Recro Pharma – Consensus Indicates Potential 152.5% Upside

Broker Ratings

Recro Pharma found using ticker (REPH) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 10 and 5 calculating the average target price we see 7.5. Now with the previous closing price of 2.97 this would imply there is a potential upside of 152.5%. The day 50 moving average is 2.28 and the 200 day moving average is 3.02. The market capitalisation for the company is $78m. Find out more information at:

Recro Pharma a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products to pharmaceutical market in the United States and internationally. The company was formerly known as Recro Pharma I and changed its name to Recro Pharma in August 2008. Recro Pharma was founded in 2007 and is based in Malvern, Pennsylvania.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index